A 58-year-old man with type 2 diabetes mellitus and chronic kidney disease (eGFR 28 mL/min/1.73 m²) presents to the emergency department with palpitations and muscle weakness. He was started on lisinopril 2 weeks ago for hypertension. On examination, blood pressure is 145/92 mmHg, heart rate 92/min and regular. ECG shows peaked T waves in precordial leads and prolonged PR interval. Serum potassium is 7.2 mEq/L, sodium 138 mEq/L, creatinine 2.8 mg/dL, and pH 7.32. What is the most appropriate immediate management?

Explanation

## Clinical Context This patient presents with **symptomatic hyperkalemia** (K⁺ = 7.2 mEq/L) with **ECG changes** (peaked T waves, prolonged PR interval) indicating **cardiac membrane instability**. The combination of CKD, ACE inhibitor use, and metabolic acidosis (pH 7.32) creates a perfect storm for life-threatening hyperkalemia. ## Immediate Management Algorithm ```mermaid flowchart TD A[Hyperkalemia with ECG changes]:::urgent --> B{Cardiac toxicity present?}:::decision B -->|Yes: peaked T, PR prolongation| C[Calcium gluconate IV]:::action C --> D[Stabilize cardiac membrane]:::outcome D --> E[Shift K intracellularly:<br/>Insulin + Dextrose]:::action E --> F[Monitor response]:::outcome B -->|No ECG changes| G[Kayexalate + diuretics<br/>Consider dialysis]:::action ``` ## Why Calcium Gluconate First? **Key Point:** Calcium does NOT lower serum potassium. It **antagonizes the cardiac effects** of hyperkalemia by stabilizing the cardiac action potential threshold. - **Onset:** 1–3 minutes (fastest cardiac protection) - **Duration:** 30–60 minutes - **Mechanism:** Increases the voltage gradient between resting potential and threshold, reducing excitability - **Dose:** 10% calcium gluconate 10–20 mL IV over 2–5 minutes; may repeat in 5 minutes if ECG changes persist ## Subsequent Potassium-Lowering Therapies | Intervention | Mechanism | Onset | Duration | K⁺ Reduction | |---|---|---|---|---| | **Insulin + Dextrose** | Shifts K⁺ into cells via Na⁺-K⁺-ATPase | 10–20 min | 4–6 hrs | 0.5–1.2 mEq/L | | **β₂-agonist (albuterol)** | Stimulates Na⁺-K⁺-ATPase | 30 min | 4–6 hrs | 0.5–1.0 mEq/L | | **Sodium bicarbonate** | Alkalinizes; shifts K⁺ intracellularly | 30–60 min | 2–4 hrs | 0.3–0.5 mEq/L (unreliable in acidosis) | | **Kayexalate (polystyrene)** | GI potassium binding & elimination | 2–12 hrs | 4–24 hrs | 0.5–1.0 mEq/L | | **Loop diuretics** | Renal K⁺ excretion (only if urine output adequate) | 30 min | 4–6 hrs | Variable; ineffective in CKD | | **Hemodialysis** | Extracorporeal K⁺ removal | Immediate | Ongoing | 1–2 mEq/L per hour | ## Why This Patient Needs Calcium + Insulin/Dextrose **Clinical Pearl:** In **symptomatic hyperkalemia with ECG changes**, the sequence is: 1. **Stabilize the heart** (calcium) — buy time 2. **Shift K⁺ intracellularly** (insulin + dextrose) — rapid reduction 3. **Remove K⁺ from body** (dialysis, diuretics, kayexalate) — definitive This patient's metabolic acidosis (pH 7.32) worsens hyperkalemia by driving K⁺ out of cells in exchange for H⁺. Insulin + dextrose is the fastest intracellular shift agent and works even in acidosis. **High-Yield:** Kayexalate is **slow** (2–12 hours) and **unreliable** in CKD; it is never first-line for symptomatic hyperkalemia. Loop diuretics are **ineffective** when eGFR < 30 mL/min. ## Why Dialysis Is Not Monotherapy Hemodialysis is definitive but takes time to set up. **Immediate cardiac protection and K⁺ shifting must happen first** while dialysis is being arranged. This patient will need dialysis eventually (given CKD stage 3b and ACE inhibitor-induced hyperkalemia), but not as the sole initial intervention.